Clinical evaluation of Hyprost capsules in the management of Benign Prostatic Hyperplasia

Phase 4

Not yet recruiting

• Conditions: Benign prostatic hyperplasia. Ayurveda Condition: Mutraghatah,

• Registration Number: CTRI/2023/06/053675
• Lead Sponsor: Zoetic Ayurevedics Pvt. Ltd. Ahmedabad, Gujarat

Brief Summary

Benign prostate hyperplasia is a common clinical entity in after 50 years of male patients.  Irritative and obstructive symptoms with progressive age make condition more  worse. In proposed clinical trial the outcome assesment will be assess according to relieve in obstructive as well as irritative symptoms.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2023-07-06
• Study Start: 2023-07-14

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: Male
• Target Recruitment: 150

Inclusion Criteria

• Patients having signs and symptoms of BPH.
• Grade 1 to Grade 3 BPH Weight of prostate gland-30-85 g Patient with Sr. PSA value <4ng/ml Uroflomerty with peak flow rate between 10-15ml /sec Patients with IPSS Score 0-35 (complete range taken).

Exclusion Criteria

• Age below 40 years.
• Patients of malignancy, congenital deformities of urogenital tract or any abdomino- pelvic pathology other than BPH.
• Patients of uncontrolled Diabetes mellitus (FBS: >140mg/dl, PPBS:>180mg/dl) Patient of Uncontrolled Hypertension ICD-10(BP >140/90 mm of Hg) Known case of cardiac diseases like IHD, MI, CAD.
• Congenital deformities of urogenital tract or any abdomino- pelvic pathology other than BPH.
• Systemic diseases like Tuberculosis, Paralysis, Parkinsonism history of MI, etc.
• will be excluded.
• Patients with history of catherization, retention, hydronephrosis or impaired kidney function will be excluded.
• Patients with USG findings of PVRU > 100ml Patients with evidence of Prostatic malignancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relieve in Sign and symptoms of LUTS	After completion of 60 days intervention

Secondary Outcome Measures

Name	Time	Method
Reduce size of prostate	8 weeks

Trial Locations

Locations (1)

UG hospital, gulab kunwarba ayurved hospital ITRA; 🇮🇳 Jamnagar, GUJARAT, India

UG hospital, gulab kunwarba ayurved hospital ITRA

🇮🇳Jamnagar, GUJARAT, India

Dr TS Dudhamal

Principal investigator

9428671939

dudhamal@itra.edu.in